We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassays Correlated With Systemic Lupus Erythematosus Activity

By LabMedica International staff writers
Posted on 15 Sep 2011
Print article
Three immunoassays have been compared for their ability to monitor the progression of the disease systemic lupus erythematosus (SLE).

Quantitative measurement of anti-double stranded DNA (dsDNA) antibodies plays a central role in monitoring the autoimmune connective tissue disease SLE, and results are incorporated into the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K).

Scientists at the University Health Network (Toronto, ON, Canada) analyzed 105 patient samples for anti-dsDNA antibodies and results were interpreted as positive or negative according to manufacturer cut-off limits. A multiplex anti-dsDNA immunoassay and an enzyme anti-dsDNA immunoassay assay were investigated as potential alternatives to the Farr-radioisotope immunoassay (RIA).

The BioPlex 2200 multiplex immunoassay (BPx, Bio-Rad Laboratories; Hercules, CA, USA) and the Quanta Lite “Farrzyme” enzyme immunoassay (EIA, INOVA Diagnostics; San Diego, CA, USA) met the stated analytical performance claims, but EIA maintained the widest measurable range. Only 33% SLE patients tested positive on BPx and only 31% with the EIA as compared with the 48% for Farr-RIA. Correlation between Farr-RIA and BPx assay results was poor with 62% positive agreement and 85% negative agreement. There was also poor correlation between the Farr-RIA and EIA with 56% lower positive agreement, but a better negative agreement of 91%.

The mean SLEDAI-2 K scores differed significantly between positive and negative result groups for Farr-RIA and BPx, but not for EIA and the authors suggest suggests it may be appropriate to lower the EIA cut-off point. The authors concluded that the optimal alternative for the Farr-RIA assay remains equivocal. There are ongoing analyses of clinical follow-up and anti-dsDNA measurements, which will aid in determining the most appropriate alternative. The article was published on August 15, 2011, in the journal Clinical Biochemistry.

Related Links:
University Health Network
Bio-Rad Laboratories
INOVA Diagnostics



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.